Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)
The aim of this phase Ⅱ study is to evaluate the efficacy and safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC.
Non-Small-Cell Lung Cancer
DRUG: Furmonertinib (160mg)
One-year Progression Free Survival Rate, Percentage of subjects still alive and progression free one year after inclusion in the study., One year after inclusion
One-year Overall Survival Rate, Percentage of subjects still alive one year after inclusion in the study., one year after inclusion|Progression Free Survival, The time from the first does of the study drugs to the progression of the disease or death for any reason., Approximately 2 years following the first dose of study drugs|Objective Response Rate, Proportion of subjects whose tumors were assessed as complete response(CR) or partial response(PR) according to RECIST 1.1., Approximately 2 years following the first dose of study drugs|Adverse Events, Number of participants with adverse events as a measure of safety and tolerability., Until 28 days from the last dose of study drugs or initiation of a new anticancer treatment
The aim of this phase Ⅱ study is to evaluate the efficacy and safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC.